This volume of the Subcellular Biochemistry series is the result of the long-standing research interest of the editor in the molecular mechanism underlying Alzheimer's disease and other amyloid diseases, indicated also by the earlier book in the series (Volume 38), devoted to Alzheimer's disease. The broad coverage within the present amyloidogenesis book represents an attempt to collate current knowledge relating to the proteins and peptides involved in most of the known amyloid diseases, together with some amyloid/fibril-forming proteins and peptides that are not involved in diseases. Thus, the range of topics included is comprehensive and furthermore it was thought appropriate to include both basic science and clinical presentation of the subjects under discussion.

This book is unique in that it contains both Basic Science and Clinical consideration of the amyloid diseases Up-to-date knowledge is presented by authoritative researchers and clinicians The broad range of techniques used to study amyloidogenesis is clear from the topics included in the book Some emphasis appears relating the cytotoxicity of protein oligomers as well as fibrils in the genesis of amyloid disease Includes supplementary material: sn.pub/extras Includes supplementary material: sn.pub/extras

Klappentext

This volume of the Subcellular Biochemistry series is devoted to the aggregation and fibrillogenesis of the amyloid-forming peptides and proteins, including emphasis on oligomer formation as well as fibril formation. The diverse topics included here are presented within 22 chapters, covering many of the relevant topics from both a basic science and clinical perspective. The authorship of these chapters is thoroughly international, with authoritative contributions from active researchers. Fundamental structural and cellular studies using many different technical approaches are presented, leading through to clinical and therapeutic aspects of the amyloid diseases, considered from both pharmaceutical and natural product view points. It is hoped that this book will be of use to both biomedical scientists and clinicians wishing to keep abreast of this rapidly advancing field, of direct importance to the understanding of cerebral neurodegenerative disease and systemic amyloid disease.

Inhalt

1. Introduction and Technical Survey. - 2. Fibril Formation by Short Synthetic Peptides. - 3 . ** In vitro Oligomerization and Fibrillogenesis of Amyloid-beta Peptides. - 4. Tau Fibrillogenesis. - 5. Prion protein Aggregation and Fibrillogenesis In vitro. - 6. -Synuclein Aggregation and Modulating Factors. - 7. Pathological Self-aggregation of 2 -microglobulin: A Challenge for Protein Biophysics. - 8. Islet amyloid polypeptide Aggregation and fibrillogenesis in vitro and its Inhibition. - 9. Mechanisms of Transthyretin Aggregation and Toxicity. - 10. Fibrillogenesis of Huntingtin and Other Glutamine Containing Proteins. - 11. Aggregation and Fibrillogenesis of Proteins not Associated with Disease A few Case Studies. - 12. Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs. - 13. Experimental inhibition of fibrillogenesis and neurotoxicity by amyloid-beta (A) and other disease-related peptides/proteins by plant extracts and herbal compounds. - 14. Alzheimer's Disease. - 15. Modeling the Polyglutamine Aggregation Pathway in Huntington's Disease: from Basic Studies to Clinical Applications. - 16. Parkinson's Disease. - 17. Human Prion Diseases: From Kuru to Variant Creutzfeldt-Jakob Diseasae. - 18. Animal Prion Diseases. - 19. 2 -microglobulin Amyloidosis. - 20. Systemic AA Amyloidosis. - 21. Familial Amyloidotic Polyneuropathy and Transthyretin. - 22. The Challenge of Systemic Immunoglobulin Light-chain Amyloidosis (AL).